Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC2731 injection in adults with chronic rhinosinusitis with nasal polyps (CRSwNP)
CTR20252832Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Sep 2025
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing TQC2731 arm with Placebo arm (2 arms). Primary endpoints: Change in nasal polyp score (NPS) at week 24 in CRSwNP subjects, Change in nasal congestion score (NCS) at week 24 in CRSwNP subjects and 2 more. Started Sep 2025; status: active.
02
Drugs
bosakitug
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20252832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252832.